Open main menu

Pandion Therapeutics is an early-stage biotech company developing engineered T cells for autoimmune diseases. It is currently developing PT101, is a combination of our interleukin-2 mutein effector module with a protein backbone designed to selectively expand regulatory T cells without activating proinflammatory cells. It was founded in 2017 in Watertown, MA.[1]

Pandion Therapeutics
Private
IndustryBiotechnology
Founded2017; 4 years ago (2017)
HeadquartersWatertown, MA,
USA
Key people
  • Rahul Kakkar (CEO}
  • Jo Viney (Co-founder)
ProductsEngineered T cells
Websitepandiontx.com

References

  1. Capital, Contributor Renaissance Capital Renaissance. "Autoimmune disease biotech Pandion Therapeutics files for a $75 million IPO". www.nasdaq.com. Retrieved 2020-06-29.

External links